LEWISVILLE, Texas, Aug. 15, 2012 /PRNewswire/ -- med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics' TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.
med fusion, an integrated laboratory reference testing and clinical trial services company located in Lewisville, TX, announced today it has entered into a Market Development Agreement with Theranostics Health, Inc., of Rockville, MD, to clinically validate diagnostic assays based on measuring the activation status of signal transduction pathways important to the development and growth of human cancers. Theranostic's TheraLink™ Assays are designed to provide oncologists with a molecular map based on each individual cancer's unique pattern of aberrant signaling. This approach will allow oncologist to exploit each tumor's individual molecular profile and therefore provide truly personalized treatment to each patient. In addition, the companies will jointly conduct promotional, marketing and sales-related efforts, technology integration, as well as other activities aimed at the clinical services, clinical trials, diagnostic, theranostic and personalized healthcare markets.
Under the terms of the agreement, the companies will work together to provide clinical validation of the TheraLink™ Assays through clinical trials conducted by med fusion as well as through other oncology practices associated with med fusion. The TheraLink™ Assays will provide oncologists access to information about the activity of signaling pathways that are out of control in cancer and the activity of drug targets in these pathways as they seek to provide better care for their patients.
"This Market Develop